Hairy cell leukemia and COVID-19 adaptation of treatment guidelines is a research paper published in Leukemia (2021). On theSindex it has a DataRank of 0.578. It has been cited 46 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.578
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NCI NIH HHS
Grant: P30 CA008748
Canadian Institutes of Health Research
Grant: unidentified
unidentified
Hairy Cell Leukemia Foundation, the Leukemia and Lymphoma Society and the Associazione Italiana Ricerca sul Cancro (AIRC).
Pfizer
Pharmacyclics, Janssen, AstraZeneca, TG Therapeutics, Merck, AbbVie, and Ascentage Pharma
TG Therapeutics
Hairy Cell Leukemia Research Foundation
AstraZeneca
Funding through the University of Rochester for laboratory research, from Acerta/AstraZeneca and TG Therapeutics, and from the Hairy Cell Leukemia Foundation
Innate, Gennetech
Janssen, AbbVie and Beigene
MingSitght Pharmaceuticals
AbbVie
Novartis
Royal Marsden NHS Foundation Trust
Teva Pharmaceutical Industries
AstraZeneca, Medimmune, Roche, Janssen, Abbvie
BMS, Amgen, Xencor, Macrogenics, Orsenix, Abbvie, Taiho, Prelude, Astex
Janseen and Cilag SPA
Genentech, Servier, Takeda, Fate Therapeutics and Amgen
FWCI
4.66
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals